Lung Cancer Multimodal Treatment / 肺癌多模式综合治疗

Definition

Lung cancer multimodal treatment is the coordinated selection and sequencing of surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and follow-up according to tumor type, stage, molecular findings, operability, patient condition, and treatment response.

Current Synthesis

VOL.104 presents lung-cancer care as a pathway rather than a contest between an old surgical model and newer drugs. The episode distinguishes small-cell from non-small-cell lung cancer at a public-education level, then argues that modality choice depends on biology and stage: a treatment may be primary in one setting, inappropriate in another, or used before and after surgery as part of a sequence.

The practical test proposed by the source is whether the care team can make the whole route legible. A patient should be able to understand the current objective, why one modality comes first, what later treatments or referrals may follow, and how the plan can change with pathology, mutation findings, response, recovery, or recurrence risk.

Key Claims

• Histology, stage, molecular findings, operability, and patient condition shape treatment selection.
• Surgery can remain central for selected non-small-cell lung cancers without becoming the only relevant treatment.
• Radiation and systemic therapies can be primary, neoadjuvant, adjuvant, or later-line components depending on context.
• Newer targeted and immune therapies complement rather than automatically eliminate surgery, radiotherapy, or chemotherapy.
• A legible longitudinal plan should explain objectives, sequence, referral points, and conditions that would change the route.

Evidence

• Histology and modality: VOL.104胸外科｜肺结节是什么？哪种肺结节会发展成肺癌？吐黑水排黑便就是排毒了吗 contrasts small-cell and non-small-cell lung cancer to explain why surgery has different roles.
• Sequencing: VOL.104胸外科｜肺结节是什么？哪种肺结节会发展成肺癌？吐黑水排黑便就是排毒了吗 gives a source-scoped example in which chemotherapy, surgery, further chemotherapy, and targeted therapy form one treatment path.
• Whole-route communication: VOL.104胸外科｜肺结节是什么？哪种肺结节会发展成肺癌？吐黑水排黑便就是排毒了吗 proposes the clinician’s ability to explain the continuing plan and handoffs as a useful patient-facing signal.

Counterevidence & Qualifications

This page is grounded in one public podcast explanation, not a current lung-cancer guideline. The source’s disease categories and example sequences are simplified; actual care can depend on detailed pathology, TNM stage, biomarkers, resectability, performance status, organ function, comorbidity, prior treatment, adverse effects, patient goals, local approvals, and multidisciplinary review. A coherent explanation is valuable but does not by itself prove that a plan is evidence-based or optimal.

What Changed

• Created the concept from VOL.104’s whole-path account of surgery, radiation, chemotherapy, targeted therapy, and immunotherapy.

Related Concepts

• Hospital Capability–Patient Complexity Matching / 医院能力与患者复杂度匹配 - institutional-routing frame for coordinated oncology resources and comorbidity support.
• Doctor-Patient Communication - process for making treatment objectives, sequence, and uncertainty understandable.
• Medical Diagnostic Reasoning - reasoning layer that combines pathology, imaging, stage, molecular findings, and response.
• Clinical Trust Building / 临床信任建立 - relationship needed to carry a changing plan without converting explanation into certainty.